While resmetirom has been primarily used to treat advanced stages of non-cirrhotic MASH, it is predominantly liver-directed and does not address the high burden of obesity, type 2 diabetes and cardio-renal risk that characterises most patients with MASH
TABLE 7 Summary of clinical trials investigating curcumin formulations in different types of cancer
Why people switch: Some switch because of cost, insurance changes, side effects, or because weight loss has slowed, and they want to try a different option
System, not bundle, when it has One coherent design logic across products GLP-1-appropriate dosing in every piece Consistent low-sugar, easy-tolerance formulation Convenient single-serve formats A physician's fingerprints on the formulation Based on publicly available label data as of May 2026
A: According to ro.co , eligibility requirements include: Age 18+ (some services may require 21+) Resident of state where Ro operates weight loss services BMI 30 (obesity) OR BMI 27 (overweight) with at least one weight-related condition No personal or family history of medullary thyroid carcinoma (MTC) No Multiple Endocrine Neoplasia syndrome type 2 (MEN 2) Not pregnant, planning pregnancy within 2 months, or breastfeeding No contraindications for GLP-1 medications Provider approval required based on comprehensive medical evaluation Meeting basic eligibility doesn't guarantee medication approval
Report this to your physician and replace the pen with a new one
